Combining natriuretic peptides and necrosis markers in determining prognosis in heart failure

Reviews in Cardiovascular Medicine

Volumn 4, Issue SUPPL. 4, 2003, Pages

  Fonarow, Gregg C ^a   Horwich, Tamara B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

B type natriuretic peptide; Heart failure; Troponin

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; TROPONIN I; TROPONIN T; VALSARTAN;

ARTICLE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; EMERGENCY HEALTH SERVICE; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART VENTRICLE FUNCTION; HEMODYNAMICS; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE; MEDICAL ASSESSMENT; MORTALITY; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SUDDEN DEATH; SURVIVAL TIME;

BIOLOGICAL MARKERS; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NECROSIS; PREVALENCE; PROGNOSIS; TROPONIN; UNITED STATES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0141995033     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. American Heart Association. 2003 Heart and Stroke Statistical Update. Dallas: American Heart Association; 2002.
2. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:2007-2018.
3. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2001;38:2101-2113.
4. Bozkurt B, Mann DL. Use of biomarkers in the management of heart failure: are we there yet? Circulation. 2003;107:1231-1233.
5. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321-328.
6. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577-585.
7. Maisel A. B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure. What's next? Circulation. 2002;105:2328-2331.
8. Harrison A, Morrison LK, Krishnaswamy P, et al. B-type natriuretic peptide (BNP) predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med. 2002;39:131-138.
9. Berger R, Huelsman M, Stecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002;105:2391-2396.
10. Vrtovec B, Reynolds D, Zewail A, et al. Prolonged QTc interval and high B-type natriuretic peptide levels together predict mortality in patients with advanced heart failure. Circulation. 2003;107:1764-1769.
11. Koglin J, Pehlivanli S, Schwaiblmair M, et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol. 2001;38:1934-1941.
12. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001;37:386-391.
13. Anand IS, Fisher LD, Chiang Y-T, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in Val-HeFT. Circulation. 2003;107:1278-1283.
14. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014-1021.
15. Chen HH, Burnett JC. Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep. 2000;2:198-205.
16. Fonarow GC, Hamilton MA, Moriguchi J, et al. Hemodynamic predictors of clinical outcomes in decompensated advanced heart failure. J Card Fail. 2001;7:38.
17. Crilley JG, Farrer M. Left ventricular remodeling and brain natriuretic peptide after first myocardial infarction. Heart. 2001;86:638-642.
18. Tsutamoto T, Wada A, Maeda K. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509-516.
19. Richards AM, Doughty R, Nicholls MG, et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation. 1999;99:786-792.
20. Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001;37:1228-1233.
21. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000; 355:1126-1130.
22. Antman EM., Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996;335:1342-1349.
23. Meier MA, Al-Badr WH, Cooper JV, et al. The new definition of myocardial infarction: diagnostic and prognostic implications in patients with acute coronary syndromes. Arch Intern Med. 2002;162:1585-1589.
24. Sato Y, Yamada T, Taniguchi R, et al. Persistently increased serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation. 2001;103:369-374.
25. LaVecchia LL, Mezzena G, Zanolla L, et al. Cardiac troponin I as a diagnostic and prognostic marker in severe heart failure. J Heart Lung Transplant. 2000;19:644-652.
26. Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation. 1997;96:2953-2958.
27. Setsuta K, Seino Y, Takahashi N, et al. Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. Am J Cardiol. 1999;84:608-611.
28. Del Carlo CH, O'Connor CM. Cardiac troponins in congestive heart failure. Am Heart J. 1999;138:646-653.
29. Ishii J, Nomura M, Nakamura Y, et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol. 2002;89:691-695.
30. Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality in advanced heart failure. Circulation. 2003; 108:833-838.
31. Perna ER, Macin SM, Pozzer DL. Ventricular dyssynchrony in heart failure: clinical profile, ongoing myocardial damage and long-term prognosis. J Card Fail. 2002;8:S46.
32. Wu AHB, Ford L. Release of cardiac troponin in acute coronary syndromes: ischemia or necrosis? Clin Chim Acta. 1999;284:161-174.
33. Mann, DL. Mechanisms and models in heart failure. Circulation. 1999;100:999-1008.
34. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Eng J Med. 1997;336:1131-1141.
35. Anversa P, Kajstura J. Myocyte cell death in the diseased heart. Circ Res. 1998;82:1231-1233.
36. Cheng W, Li B, Kajstura J, et al. Stretch-induced programmed myocyte cell death. J Clin Invest. 1995;96:2247-2259.
37. Feng J, Schaus BJ, Fallavolita JA, et al. Preload induces troponin I degradation independently of myocardial ischemia. Circulation. 2001; 103:2035-2037.
38. Giannitsis E, Müller-Bardorff M, Kurowski V, et al. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation. 2000;102:211-217.
39. Kollef MH, Ladenson JH, Eisenberg PR. Clinically recognized cardiac dysfunction: an independent determinant of mortality among critically ill patients. Chest. 1997;111:1340-1347.
40. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000;36:517-522.
41. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002;105:1760-1763.